Skip to Content

Express Scripts Statement on Administration's Comments on Drug Pricing

May 11, 2018 at 2:58 PM EDT

ST. LOUIS, May 11, 2018 /PRNewswire/ -- Express Scripts (NASDAQ: ESRX) released the following statement in response to the Administration's announcement today on prescription drug costs:

Express Scripts, St. Louis, Missouri. (PRNewsfoto/Express Scripts)

"President Trump rightly recognizes drug companies charge way too much, and their prices need to come down. Express Scripts leads the way in reining in costs and improving care. By taking on tough challenges, we helped employers save $32 billion on their prescription drug bill in 2017 alone. We take decisive action to improve affordability and access for the 83 million Americans we serve. For more than 30 years, Express Scripts has been a champion in the fight to lower drug costs. Express Scripts stands up to drug companies and drug stores to make sure that everyone – patients, employers, health plans, unions and public programs – get a fair deal for the money they spend. It is clear, based on today's comments, that our role has never been more important to improving healthcare."

"In particular we were pleased that the Administration recognized and endorsed policies that we have advocated for over the years, including increasing access to biosimilars, increasing the number of generic drugs available, and eliminating gag clauses and clawbacks -- anti-patient practices that we do not engage in. We look forward to working with the Administration to enact pro-patient, pro-payer policies."

About Express Scripts
Express Scripts is leading the way for tens of millions of people by aligning with plan sponsors, taking bold action and delivering patient-centered care to make better health more affordable and accessible.

Headquartered in St. Louis, Express Scripts provides a full range of integrated pharmacy benefit management services, including home delivery pharmacy care, specialty pharmacy care and benefit management, benefit-design consultation, drug utilization review, formulary management and medical and drug data analysis, that guide patients and plans toward better health by prioritizing care and increasing savings. Our services drive down the cost of care for employer-funded, Medicare, Medicaid and Public Exchange plans, and create the headroom needed to keep patients' cost-share low, access broad, and do more for those who are challenged by high out-of-pocket costs. Express Scripts also distributes a full range of biopharmaceutical products and offers innovative medical benefit management services.

For more information, visit Lab.Express-Scripts.com or follow @ExpressScripts on Twitter.

Media Contact:

Phil Blando
202-383-7982
pjblando@express-scripts.com

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/express-scripts-statement-on-administrations-comments-on-drug-pricing-300647163.html

SOURCE Express Scripts